



Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

SGX ANNOUNCEMENT

Telix Announces Exercise of Optional Redemption Right of Outstanding Convertible Notes Due 2029

Melbourne (Australia) and Indianapolis, IN (U.S.) – September 24, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it is giving notice of its intention to exercise its optional redemption right to redeem and cancel all its outstanding convertible notes due 2029, issued by Telix under the trust deed dated July 30, 2024 (the “Notes”). This is being undertaken in accordance with Condition 7(b)(ii) of the Terms and Conditions of the Notes.

This follows the announcement on April 23, 2026, regarding the successful completion of the repurchase of approximately A\$637 million in principal of the A\$650 million 2.375% Convertible Bonds due 2029.

The terms of the redemption specified in accordance with Condition 7(d) of the Notes are set out below.

Optional Redemption Date	October 29, 2026
Redemption price	The Notes will be redeemed at their principal amount together with accrued but unpaid interest to (but excluding) the Optional Redemption Date, calculated in accordance with the Conditions.
Aggregate principal amount of Notes outstanding	A\$3,900,000 (as at September 23, 2026, being the latest practicable date prior to publication).
Conversion Price	A\$24.7775 (as at September 23, 2026, being the latest practicable date prior to publication).
Closing Price of Ordinary Shares	A\$16.08 (as at September 23, 2026, being the latest practicable date prior to publication).
Last day to exercise Conversion Rights	October 9, 2026, such that the related Conversion Date falls no later than October 15, 2026 (being the 10 th business day prior to the Optional Redemption Date). Noteholders wishing to exercise Conversion Rights must do so in accordance with the Conditions and applicable clearing system procedures on or before this date.

Noteholders who wish to exercise their Conversion Rights must do so no later than October 9, 2026, such that the related Conversion Date falls no later than October 15, 2026 (being the 10th business day prior to the Optional Redemption Date), in accordance with the Terms and Conditions and applicable clearing system procedures.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.

Telix's commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the

U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F18) approved by the FDA for glioma imaging. The Company's late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (iodofalan ¹³¹I) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on [LinkedIn](#), [X](#) and [Facebook](#).

Investor Relations

Annie Kasparian
annie.kasparian@telixpharma.com

Charlene Jaw
charlene.jaw@telixpharma.com

Legal Notices

This announcement does not constitute or form part of any offer to purchase, a solicitation of an offer to purchase, an offer to sell or an invitation or solicitation of an offer to sell, issue or subscribe for any securities.

Neither this announcement nor any copy hereof may be taken into or distributed in the United States.

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form any part of any offer or solicitation to purchase or subscribe for securities in the United States. The Convertible Notes, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Notes and the guarantees are being offered and sold solely outside the United States in an "offshore transaction" as defined in, and in reliance on Regulation S under the Securities Act.

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction, and neither this announcement or anything attached to this announcement shall form the basis of any contract or commitment.

The Redemption is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Notes may not be tendered in the Redemption by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Notes made by a person located in the United States will not be accepted.

This communication may not be distributed to the press or other media or forwarded, photocopied, passed on or, in any other manner, transmitted to any other person. Non-compliance with the foregoing may constitute a violation of law. This information is subject to change.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

©2026 Telix Pharmaceuticals Limited. All rights reserved.